Schizophrenic Disorders Clinical Trial
Official title:
Interest of EMDR (Eye Movement Desensitization and Reprocessing) Psychotherapy in the Management of Schizophrenic Disorders
The purpose of this study is to determine the interest of the use of EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the management of psychotic disorders, in particular schizophrenic disorders.
Since 2015 more and more studies conducted by researchers, especially Dutch and English, are interested in the use of EMDR (Eye Movement Desensitization and Reprocessing) for other pathologies such as bipolar disorder, unipolar depression, anxiety disorders, psychotic disorders, substance use disorders and chronic pain. These studies show that EMDR appears to be a technique that is both effective, capable of significantly improving symptoms, and without risk for patients, while respecting the protocol and the clinical stabilization provided during the procedure. To date, the use of EMDR for the management of psychotic patients has not been the subject of any prospective study in France and the authors' conclusions converge on the fact that it is essential to carry out more research on the subject. For this, the investigators wish to evaluate the effect of EMDR on the management of patients with schizophrenic disorders, on the basis that this psychotherapy would improve their quality of life (improvement of all the specific scores used in psychiatry). : PANSS, DES, HAD and WEMWBS scales). Finally, the investigators believe that it is relevant to assess the benefit of EMDR six months after hospitalization of patients, in order to measure the maintenance of this efficacy in the medium term ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04608032 -
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
|
N/A | |
Terminated |
NCT00660595 -
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
|
Phase 3 | |
Completed |
NCT02655172 -
Have a Good Grasp of the Worldthe World
|
N/A | |
Completed |
NCT01729650 -
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
|
N/A | |
Completed |
NCT01606436 -
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
|
Phase 1 | |
Completed |
NCT02525315 -
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations
|
Phase 2 | |
Completed |
NCT00488319 -
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
|
Phase 3 | |
Completed |
NCT00088491 -
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
|
Phase 3 | |
Completed |
NCT01279213 -
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
|
Phase 4 | |
Completed |
NCT00600756 -
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
|
Phase 3 | |
Completed |
NCT00572247 -
The Psychiatric Rehabilitation Approach to Weight Loss
|
N/A | |
Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
Completed |
NCT00485823 -
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
|
Phase 4 | |
Active, not recruiting |
NCT00161408 -
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
|
N/A | |
Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
Completed |
NCT00088465 -
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
Withdrawn |
NCT02654405 -
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT02544516 -
Upside Down, Give me the Handle
|
N/A | |
Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 |